Abstract
This paper presents and illustrates methodology for specifying, estimating, and evaluating a predictive model for repeated measures time-to-event responses. The illustrative example specifies a model of the antiemetic effect vs. concentration relationship for the 5-HT 3 antagonist ondansetron in the human ipecac model for emesis. A key part of this model is a time-dependent log hazard function for emesis that is increased by ipecac administration and decreased by ondansetron concentration. The model is fit using an approximate maximum likelihood method. The data consist of the time free of emeses and, for those individuals with emetic episodes, the time(s) of the episode(s). Model evaluation is accomplished using residual plots adapted to time-to-event data and a “posterior predictive check” wherein observed data statistics are compared to those obtained from data simulated from the fitted model. The ondansetron concentration required to obtain a 50% reduction in the hazard of emesis is estimated to be 1.4±0.2 ng/ml, and the rate constant for elimination of ipecac-induced hazard is 1.5±0.2hr −1 .
Similar content being viewed by others
REFERENCES
N. H. G. Holford, J. P. R. Monteleone, H. C. Ko, and C. C. Peck. Ann. Rev. Pharmacol. Toxicol. 40:209–234 (2000).
J. Dingemanse, M. Danhof, and D. D. Breimer. Pharmacokinetic-pharmacodynamic modelling of CNS drug effects. Pharmacol. Ther. 38:1–52 (1988).
J. W. Blue and W. A. Coburn. Efficacy measures: surrogates or clinical outcomes? J. Clin. Pharmacol. 36:767–770 (1996).
M. E. Ausems, C. C. Hug, Jr., D. R. Stanski, and A. G. Burm. Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery. Anesthesiology 65:362–373 (1986).
L. B. Sheiner. A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data. Clin. Pharmacol. Ther. 56:309–322 (1994).
J. W. Mandema and D. R. Stanski. Population pharmacodynamic model for ketorolac analgesia. Clin. Pharmacol. Ther. 60:619–635 (1996).
L. B. Sheiner, S. L. Beal, and A. Dunne. Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials. J. Am. Statist. Assoc. 92:1235–1244 (1997).
D. J. Sargent. A general framework for random effects survival analysis in the Cox proportional hazards setting. Biometrics 54:1486–1497 (1998).
N. Minton, R. Swift, C. Lawlor, T. Mant, and J. Henry. Ipecacuanha-induced emesis: A human model for testing antiemetic drug activity. Clin. Pharmacol. Ther. 54:53–57 (1993).
P. V. Colthup, C. C. Felgate, J. L. Palmer, and N. L. Scully. Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly. J. Pharm. Sci. 80:868–871 (1991).
S. A. Wring, R. M. Rooney, C. P. Goddard, I. Waterhouse, and W. N. Jenner. A sensitive radioimmunoassay, combined with solid phase extraction, for the subnanogram per ml determination of ondansetron in human plasma. J. Pharm. Biomed. Anal. 12:361–371 (1994).
S. L. Beal and L. B. Sheiner. NONMEM User's Guides. UCSF: NONMEM Project Group, 1992.
C. Veyrat-Follet, E. Fuseau, R. Farinotti, and J. Palmer. Population pharmacokinetics of ondansetron: Model building approaches. J. Pharmacokin. Biopharm. 2000: submitted.
S. Ross. Stochastic Processes, Wiley, New York, 1983.
J. D. Kalbfleisch and R. L. Prentice. The Statistical Analysis of Failure Time Data, Wiley, New York (1980).
T. M. Therneau, P. M. Grambsch, and T. R. Fleming. Martingale-based residuals for survival models. Biometrika 77:147–160 (1990).
D. Collett, Modeling Survival Data in Medical Research, Chapman and Hall, London, 1994.
A. Gelman, J. B. Carlin, H. S. Stern, and D. B. Rubin (eds.). Bayesian Data Analysis, Chapman and Hall, London, 1995.
A. Gelman, X. L. Meng, and H. Stern. Posterior predictive assessment of model fitness via realized discrepancies. Stat. Sinica 6:733–807 (1996).
R. A. Maller and X. Zhou (eds.). Survival Analysis with Long-Term Survivors, Wiley, New York, 1996.
P. O. Maitre, M. Bührer, D. Thomson, and D. R. Stanski. A three-step approach combining Bayesian regression and NONMEM population analysis: Application to midazolam. J. Pharmacokin. Biopharm. 19:377–384 (1991).
J. W. Mandema, D. Verotta, and L. B. Sheiner. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J. Pharmacokin. Biopharm. 20:511–528 (1992).
D. R. Cox and E. J. Snell. A general definition of residuals (with discussion). J. Roy. Statist. Soc. A 30:248–275 (1968).
T. R. Fleming and D. P. Harrington (eds.). Counting Processes and Survival Analysis, Wiley, New York, 1991.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cox, E.H., Veyrat-Follet, C., Beal, S.L. et al. A Population Pharmacokinetic–Pharmacodynamic Analysis of Repeated Measures Time-to-Event Pharmacodynamic Responses: The Antiemetic Effect of Ondansetron. J Pharmacokinet Pharmacodyn 27, 625–644 (1999). https://doi.org/10.1023/A:1020930626404
Published:
Issue Date:
DOI: https://doi.org/10.1023/A:1020930626404